Management of Automated Insulin Pump in Potential DKA
If you suspect DKA in a patient with an automated insulin pump, immediately discontinue the pump and start intravenous insulin infusion—do not rely on the pump to manage a hyperglycemic crisis. 1, 2
Immediate Actions for Suspected DKA
Disconnect the Pump Immediately
- Disconnect the pump from the insertion cannula but leave the pump running to avoid inadvertently stopping it completely if you're unfamiliar with the device interface 3
- Start IV insulin infusion immediately upon disconnection—patients become relatively insulin deficient within one hour of pump removal 3
- Ideally, begin IV insulin at least 30 minutes before removing the pump to prevent gaps in insulin coverage, though in emergency situations this may not be possible 3
Contraindications to Continued Pump Use
The pump must be discontinued in the following situations:
- Hyperglycemic crises (DKA or HHS) 4
- Impaired level of consciousness 4
- Patient inability to correctly use pump settings or self-manage diabetes 4
- Lack of trained healthcare providers or hospital policies supporting pump use 4
IV Insulin Protocol for DKA
Initiation
- Continuous intravenous insulin infusion is the preferred method for DKA management unless the episode is mild 1, 2
- Prime IV tubing with 20 mL of insulin solution before starting the infusion to minimize insulin adsorption to plastic tubing 5
- Use the patient's hourly basal rate from their pump settings as an initial guide for IV insulin rate, then titrate to blood glucose 3
Monitoring
- Check blood glucose every 2-4 hours during DKA treatment 1, 2
- Monitor serum electrolytes, venous pH, and anion gap every 2-4 hours 1, 2
- Venous pH (usually 0.03 units lower than arterial pH) is adequate for monitoring—repeat arterial blood gases are generally unnecessary 1, 2
Resolution Criteria
DKA is resolved when:
Transitioning Back to Pump Therapy
When Patient is Stable
- Reconnect the pump and allow it to infuse at the basal rate for at least 2 hours before stopping IV insulin to establish adequate subcutaneous insulin depot 3
- Continue hourly glucose monitoring during the transition period 3
- This overlap prevents rebound hyperglycemia and ketogenesis 6
If Pump Cannot Be Restarted
- Calculate the 24-hour total basal dose from pump settings 3, 7
- Replace with long-acting insulin (glargine or detemir) in 2 divided doses 12 hours apart 3, 7
- Discontinue pump 2 hours after first injection of basal insulin 3, 7
- Maintain same insulin-to-carbohydrate ratios for mealtime boluses 3, 7
Critical Pitfalls to Avoid
Rapid Metabolic Decompensation
- Never delay IV insulin while attempting to troubleshoot the pump—disconnection from a pump renders patients relatively insulin deficient within one hour 3
- The risk of rapid hyperglycemia and ketosis upon pump cessation is significant 3
Inadequate Transition
- Abrupt discontinuation of IV insulin without adequate subcutaneous insulin overlap leads to poor glycemic control 1, 2
- Ensure 1-2 hour overlap when transitioning from IV to subcutaneous insulin 1, 2
Monitoring Errors
- Do not use nitroprusside method for ketone monitoring during treatment—it doesn't measure β-hydroxybutyrate (the predominant ketone in DKA) and may falsely suggest worsening ketosis 1, 2
- Blood β-hydroxybutyrate measurement is the preferred monitoring method 1
Special Considerations for Automated Insulin Delivery Systems
- Newer hybrid closed-loop systems (Medtronic 670G, Tandem Control-IQ, Diabeloop) have shown promise in non-critical inpatient settings, but should not be used during hyperglycemic crises 4
- Automatic threshold suspend features should be turned off in the hospital setting 4
- Research on automated insulin delivery in hospitalized patients is limited to stable, non-critical situations 4